115 related articles for article (PubMed ID: 38733419)
1. Expanding access to genetic testing for pancreatic cancer.
Rodriguez NJ; Syngal S
Fam Cancer; 2024 May; ():. PubMed ID: 38733419
[TBL] [Abstract][Full Text] [Related]
2. Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting.
Everett JN; Dettwyler SA; Jing X; Stender C; Schmitter M; Baptiste A; Chun J; Kawaler EA; Khanna LG; Gross SA; Gonda TA; Beri N; Oberstein PE; Simeone DM
Cancer Med; 2023 Feb; 12(3):2345-2355. PubMed ID: 35906821
[TBL] [Abstract][Full Text] [Related]
3. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
Furniss CS; Yurgelun MB; Ukaegbu C; Constantinou PE; Lafferty CC; Talcove-Berko ER; Schwartz AN; Stopfer JE; Underhill-Blazey M; Kenner B; Nelson SH; Okumura S; Law S; Zhou AY; Coffin TB; Rodriguez NJ; Uno H; Ocean AJ; McAllister F; Lowy AM; Lippman SM; Klein AP; Madlensky L; Petersen GM; Garber JE; Goggins MG; Maitra A; Syngal S
Cancer Prev Res (Phila); 2021 Nov; 14(11):1021-1032. PubMed ID: 34625409
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study.
Rodriguez NJ; Furniss CS; Yurgelun MB; Ukaegbu C; Constantinou PE; Fortes I; Caruso A; Schwartz AN; Stopfer JE; Underhill-Blazey M; Kenner B; Nelson SH; Okumura S; Zhou AY; Coffin TB; Uno H; Horiguchi M; Ocean AJ; McAllister F; Lowy AM; Klein AP; Madlensky L; Petersen GM; Garber JE; Lippman SM; Goggins MG; Maitra A; Syngal S
Gastroenterology; 2024 May; 166(5):872-885.e2. PubMed ID: 38320723
[TBL] [Abstract][Full Text] [Related]
5. Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.
Chittenden A; Haraldsdottir S; Ukaegbu C; Underhill-Blazey M; Gaonkar S; Uno H; Brais LK; Perez K; Wolpin BM; Syngal S; Yurgelun MB
JCO Oncol Pract; 2021 Feb; 17(2):e236-e247. PubMed ID: 33439686
[TBL] [Abstract][Full Text] [Related]
6. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
7. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.
Murali K; Dwarte TM; Nikfarjam M; Tucker KM; Vaughan RB; Efthymiou M; Collins A; Spigelman AD; Salmon L; Johns AL; Williams DB; Delatycki MB; John T; Stoita A
Hered Cancer Clin Pract; 2021 Aug; 19(1):33. PubMed ID: 34399810
[TBL] [Abstract][Full Text] [Related]
8. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
Roberts NJ; Grant RC; Gallinger S; Klein AP;
Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.
Cremin C; Howard S; Le L; Karsan A; Schaeffer DF; Renouf D; Schrader KA
Hered Cancer Clin Pract; 2018; 16():7. PubMed ID: 29541281
[TBL] [Abstract][Full Text] [Related]
11. Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.
Koptiuch C; Espinel WF; Kohlmann WK; Zhao J; Kaphingst KA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250392
[TBL] [Abstract][Full Text] [Related]
12. Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer.
Rosner G; Scapa E; Ziv T; Gluck N; Ben-Yehoyada M
Clin Transl Gastroenterol; 2024 Feb; 15(2):e00668. PubMed ID: 38147532
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.
Mohindroo C; De Jesus-Acosta A; Yurgelun MB; Maitra A; Mork M; McAllister F
Surg Pathol Clin; 2022 Sep; 15(3):491-502. PubMed ID: 36049831
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients.
Wieme G; Kral J; Rosseel T; Zemankova P; Parton B; Vocka M; Van Heetvelde M; Kleiblova P; Blaumeiser B; Soukupova J; van den Ende J; Nehasil P; Tejpar S; Borecka M; Gómez García EB; Blok MJ; Safarikova M; Kalousova M; Geboes K; De Putter R; Poppe B; De Leeneer K; Kleibl Z; Janatova M; Claes KBM
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503238
[TBL] [Abstract][Full Text] [Related]
16. Inherited predisposition to pancreatic cancer.
Hilfrank KJ; Rustgi SD; Kastrinos F
Semin Oncol; 2021 Feb; 48(1):2-9. PubMed ID: 33773812
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
Drogan CM; Kindler HL; Gao G; Kupfer SS
JCO Precis Oncol; 2023 Jan; 7():e2200196. PubMed ID: 36689696
[TBL] [Abstract][Full Text] [Related]
18. Informing models of cancer genetics care in the era of multigene panel testing with patient-led recommendations.
Underhill-Blazey M; Blonquist T; Chittenden A; Pozzar R; Nayak M; Lansang K; Hong F; Garber J; Stopfer JE
J Genet Couns; 2021 Feb; 30(1):268-282. PubMed ID: 32851753
[TBL] [Abstract][Full Text] [Related]
19. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.
Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
